Rosato E, Gigante A, Barbano B, Cianci R, Molinaro I, Rossi C et al
Wegovy (semaglutide): MHRA-approved for chronic weight management
The overall economics will also depend on the required dose and frequency of administration
In the REDEFINE 1 clinical trial, patients treated with the combination achieved a mean weight loss of 22.7% at 68 weeks, and more than 40% of participants achieved at least a 25% reduction in body weight
This is an important consideration for product formulation
Charles Jiang , a CPSBC-registered physician with over 29 years of clinical experience, oversees the medical protocols at our Richmond clinic